A large clinical trial on phase two of a drug was recently completed that shows a reduction in plaque in the brain that could slow the progression of dementia. Dr. Dan Murman is with the Department of Neurological Sciences at the University of Nebraska Medical Center, and says it is showing good promise.
Murman says there have been numerous trials before.
Phase three of the clinical trial on one medication will start soon. The turnaround time for a drug to be made available to patients is around two to five years.
